Response Genetics (RGDX) Reports Q1 Loss of $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Response Genetics, Inc. Announces First Quarter 2015 Financial Results
May 14, 2015 7:00 AM EDTLOS ANGELES, May 14, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the first quarter ended March 31, 2015.
Total revenue for the first quarter ended March 31, 2015 was $3.8 million compared to $3.9 million for the quarter ended March 31, 2014. The Company's ResponseDX® revenue was $3.3 million which was consistent with the quarter ended March 31, 2014. The Company's pharmaceutical client revenue, which varies significantly on a quarterly basis by its nature and... More
